Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On second thought,.maybe you are just hungry. Barley and Sausage is a great base for a soup.
Lol. How many shares is it? 30 million short? Do they tell you? I am guessing not but by your fervor and dedication to try and convince people to believe math isn't real, it has to be a lot.
Is that why you've been here 10-20 years ??
Yet....red today, barley up 1 penny after the weekend sausage party with the lottery club.
Always the same, gonna, might, should and could.
This thing is worth what the market says it's worth. Been that way for years.
You sound nervous,
Thanks, enjoy the day
PE Seems pretty stable staying under 10 for awhile
Looks like they want another DEA guy for the new plant.
https://www.indeed.com/cmp/Elite-Pharmaceuticals,-Inc.-1/jobs?start=0&clearPrefilter=1
Agree 100%. Very undervalued.
“A company growing doesnt mean their shares are fairly valued.”
How to say you work for someone that's heavily short here without saying you are saying you are heavily short.
Earnings and revenue don't matter. P/E doesn't matter. Billions in marketed drugs pending approval and also same in development.
About to post 55-60m in revenue before these drugs even launch
Just picked up another Billion in market products that are already approved.
Dude, just admit you are short. Or really hired to be here. I realize you may not know why.
If everyone is locked and loaded, we need some new buyers and great numbers after the CC for this to go ballistic. Hopefully, that will be the case.
Elites p/e is immaterial because it not yet stable or predictable to compare to its industry
Unlike real generic players, Elite is tiny, a pipsqueak. So , the "slightest shift" in revenues/profits can whipsaw their p/e ratio
Yes, Elite is ramping some but very little thanks to its ceo. It took lannett falling out of bed forcing the Kirko hire and pivot to SM
Thoughts
Namtae's not allowed to say. Thx for the reply.
Cost basis: $6,798.51
Gain/loss: +$676.26
Gain/loss: +9.95%
Amount: $5,000 credit card cash advance + ~$1,800 cash
What is the PE ratio currently.?? That could give you some insight to the current value.
Trading will go balistic after the CC
Everyone is Locked $$$ Loaded
Clown,
The 10-K will be filed after hours on July 1.
The Conference Call is July 2.
How many times do I have to say this?
It would not be a shock to see a Form 12b-25 late filing as Dianne stated in email she would give a weeks notice of the 10K Annual. I'm more than OK with a July 5 premarket filing with conference call on July 8 after the 4th of July weekend. New accounting firm merger and a lot of drug revenues to compute are obvious reasons IF there is a delay. Fireworks after the fireworks.
A company growing doesnt mean their shares are fairly valued.
Theres a lot that goes into this, not just a good quarter. Plenty of companies report good quarter/annuals and their stock gets hammered.
Let the market dictate, not screams of hammer time and its about to get real LMAO
Why would anyone short a stock growing exponentially '
ELTP will be grabbing as much of an $11 Billion combined IMS markets with their pipeline of drugs.
Just a handful of investors were buying Monday. Heck, one investor apparently accounted for over half of the trading volume
So it appears many arent so interested in buying more shares. Instead, attention moved to organizing hype over on reddit and other places
The storyline of continuous loading for the $multibillion buyout just isnt lining up with the facts
Speaking for The Elite Shareholders, I would like to express our gratitude for the tireless efforts you put into the Official Quarterly Revenue Guessing Game !!!!!!!!!!!!!!!!!!!!!!!
Hey Thanks A Lot King,
IB_🤴🏻
Excellent information. Hope you continue to post.
If this was the case, EVERY Nasdaq company TOMORROW MORNING would VOLUNTARILY go to the OTC because the OTC is better.
LMAO.
Oh that's right..........Nasdaq companies do EVERYTHING they possibly can to STAY on the Nasdaq.
And EVERY OTC companies goal is to GET on the Nasdaq.
Some OTC stocks are vulnerable to manipulation, and moving to NASDAQ doesn't necessarily eliminate this risk. Investors who bought in based on hype may sell off quickly, leading to price declines. The typical costs involved in uplisting from OTC to NASDAQ include:
Application fee: There is a $25,000 application fee to initiate the uplisting process.
Listing fees: The ongoing listing fees for NASDAQ range from $125,000 to $295,000.
Corporate governance changes: Companies may need to implement new corporate governance standards, such as establishing an Independent Compensation Committee, which can incur additional costs.
Financial reporting: Adapting to more stringent financial reporting requirements may require additional resources and potentially hiring new staff or consultants.
Legal and advisory fees: Companies often need to engage legal counsel and financial advisors to navigate the uplisting process, which can be a significant expense.
Potential capital raising: Some companies may need to raise additional capital to meet NASDAQ's financial requirements, such as maintaining a minimum level of shareholder equity.
Reverse stock split costs: If a company needs to increase its share price to meet NASDAQ's minimum price requirement ($4 per share), it may need to execute a reverse stock split, which involves administrative and legal costs.
Board of directors changes: Companies may need to restructure their board to meet independence requirements, potentially incurring recruitment and compensation costs.
Sarbanes-Oxley (SOX) compliance: Implementing SOX compliance measures can be a significant expense for companies uplisting to NASDAQ.
Elites move to NASDAQ
ELTP would become marginable providing a much easier, less costly means for shorting
Costs are huge? For what?
It takes time to get certain processes and structure in place, but this should be done regardless.
Cost for uplist fee and annual renewal isn’t obscene.
These are all things that should be done for a buyout regardless. Not sure what you are getting at.
You have NO CLUE what you're talking about.
EVERYTHING in your post is wrong.
I for one am struggling to understand the merits of making a move to NASDAQ for almost any reason. Moving to NASDAQ is not something to be considered lightly, the costs are huge, and we need to spend those monies on growth (future) to jack the sellout price. The only way for Elite to be approved would be a massive reverse split. That can start the death march. PLUS, plans to sell the company in the next 24/36 months so what's the point. NASDAQ benefits will not be seen for many months longer than that, it's not like turning on a light switch. Let's stop this discussion now.
What are the huge costs of moving to NASDAQ?
What are the huge costs of moving to NASDAQ?
One of the ways to get on NASDAQ is merging with a company that is already there. There are lots of possibilities. Let’s see what develops.
Elite WIPED OUT $14,684,761 in liabilities in JUST the last 3 months.
Salaries and fees: $6,934,812
Mikah profit split: $3,389,949
Hakim Promissory Note: $3,270,000
Caskey Promissory Note: $1,090,000
TOTAL PAID: $14,684,761
Conclusion: The 10-K is going to be off the charts!
I for one am struggling to understand the merits of making a move to NASDAQ for almost any reason. Moving to NASDAQ is not something to be considered lightly, the costs are huge, and we need to spend those monies on growth (future) to jack the sellout price. The only way for Elite to be approved would be a massive reverse split. That can start the death march. PLUS, plans to sell the company in the next 24/36 months so what's the point. NASDAQ benefits will not be seen for many months longer than that, it's not like turning on a light switch. Let's stop this discussion now.
My two cents regarding the several wins if move to NASDAQ - broader coverage, potential analyst coverage and a big win of indexes and more potential investors in Elite to stabilize and grow the share price. There are plenty of funds that are very short time holders or are even short holders, but the wins far outweigh the cons in uplisting to NASDAQ.
Agree. Visibility and analysts coverage
Buying on margin a company like Eltp is guaranteed bankruptcy based on the way trading firms calculate what you owe them.
Especially on Eltp where you have gap chasers and news once in a blue moon.
Can anyone explain the significance of this, if any.
It was filed back on February 20.
https://s3.amazonaws.com/sec.irpass.cc/2258/0001493152-24-007163.pdf
Reasons to uplist to Nasdaq:
1. Buy on margin
2. Visibility
Thanks.
To me the number one reason to get on NASDAQ is visibility (analyst coverage). From your previous posts, I thought you agreed. I guess that’s your number 2 reason.
This is exactly what you told us last time and it went to get it. Let’s hope you are right at least once on this board.
If the gap doesn't fill by Friday's close it will never happen.
Even though the 10-K won't be filed until Monday after the close, everyone will be buying on Monday in preparation for the after-hours filing which will show RECORD-breaking financials in EVERY aspect.
And then the conference call is the very next day.
So. Do we hit that gap before we go to nasdaq. Like you said. Gaps always get filled!!
Nasrat agrees with us.
3-4 years for buyout beginning November 2023.
Nasrat: "I think the next three, four years are going to be fantastic for us and for the stockholders."
I hope it’s closer to 3. It simply allows more time for the pipeline to grow, get launched and the value to increase.
I sent questions regarding the purchase from Nostrum, but I did not specifically ask why Nostrum agreed to the deal. Feel free to send the questions.
Why didn't you buy when I took out my $5,000 credit card cash advance?
That was the signal to buy.
Remember, EVERY time I buy the stock IMMEDIATELY goes up and goes up big.
This is the 3RD TIME it has happened.
The first time I bought it went up 40 PERCENT just 24-48 HOURS later.
The second time I bought it went nearly 50 PERCENT at the high point just 5-7 days later.
Yes please but give me a day in advance. We can be like the person on game.
When I said the GDUFA date for Generic OxyContin was June 17 I was going off the filing date.
If you go off the acceptance date the GDUFA date is July 19.
Elite Pharmaceuticals Files ANDA With US FDA To Market Opiate Analgesic Product
NORTHVALE, NJ / September 25, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.
The number one reason why we need to get to the Nasdaq ASAP is so we can buy on margin.
NASDAQ! NASDAQ! NASDAQ!
At least that’s my vote.
Did you/are you going to submit these two questions to Dianne? (see questions in quote below)
I don't want to steal your questions(I have my own), but I want to know the answers to these as well.
Please confirm you have/you will submit these two questions.
1. Why did Nostrum buy the ANDA’s from Elite if they had no intention of using them?
2. Why would Nostrum sell them back to Elite without demanding a premium?
***** 4 days *****
Caskey Promissory Note
Amount: $1,000,000 + Interest
Due: June 30, 2024
Status: Not paid
Hakim Promissory Note
Amount: $3,000,000 + Interest
Due: June 2, 2024
Status: PAID IN FULL
Official Q4 Revenue Predictions:
gebla - 11,194,939
Jimmy Joe - 12,560,939
Ramrod15 - 13,823,939
Makai63 - 14,147,185
fivebronn - 14,323,939
jour_trader - 15,003,939
supwitdacoronaz - 15,073,939
Destiny Defined - 15,509,939
fazer171 - 15,523,939
Maxthedog - 16,323,939
alstutil - 16,738,800
rocioyogi - 16,823,939
coffee880 - 16,879,494
jdd21 - 17,044,939
topki - 17,323,939
IB_ - 17,637,788
imanjen13 - 17,823,939
The ELTP Emperor - 17,864,851
mistermudler - 18,130,000
Omegaguy567 - 18,324,939
Trend-Setter - 18,538,939
tombe - 18,623,939
mrwrn2010 - 18,823,939
Sctrben - 18,954,800
HyperSeeker96 - 18,960,457
sharkey1 - 19,323,939
Django99 - 19,372,939
steve9465 - 19,523,939
oliven - 19,573,939
Lazarus Elite - 19,804,993
HGILS - 19,823,939
CMDawg - 20,181,000
SCHH - 20,211,939
The ELTP King - 20,283,126
mophron - 20,323,939
WizardGalaxy78 - 20,575,167
BZ2 - 21,185,283
NASDAQ2020 - 21,323,939
Meschan - 21,323,940
supwitdacoronaz - 21,500,000
hyder - 21,723,189
kennyt 335 - 22,323,939
Rj70 - 23,073,939
tempaussie - 23,473,939
Mirageriver2 - 24,323,939
ClearLeather - 27,593,164
littlerhody - 29,323,939
Keep your eyes peeled for the conference call press release either tomorrow or Thursday.
Thanks.
Followers
|
967
|
Posters
|
|
Posts (Today)
|
50
|
Posts (Total)
|
402218
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Elites 2024 "Official" Annual Revenue Guessing Game
Senior Moderator: IB_
Posted: 6/24/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 53 | 55,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved (On Hold - Opioid) | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 64.3M | Approved - 16 May 2024 | 8 | Elite |
Percocet | 500 M | Approved (On Hold - Opioid) | ---------- | |
Norco | 477 M | Approved (On Hold - Opioid) | ---------- | |
Methadone | 30 M | Approved (On Hold - Opioid) | ---------- | |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ---------- | ---------- |
Vyvanse | 5.1 B | Filed with FDA - 21 Dec 2023 | 14 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 9 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 Q1 | 8,980,076 | +17.04% | 1,141,809 | +273.28% |
2024 Q2 | 14,157,185 | +64.90% | 14,934,601 | +866.0% |
2024 Q3 | 15,538,800 | +68.00% | 3,500,000 | +80.0% |
FY 2024 Projected | Minimum Projected: 50,000,000 | Minimum YOY Projected Increase of 68.31% | ||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |